Publikation: Leveraging biomarkers and translational medicine for preclinical safety : Lessons for advancing the validation of alternatives to animal testing
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
European Union (EU): 964518
European Union (EU): 963845
European Union (EU): 101057014
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
This article explores the potential of principles established in translational medicine for the use of biomarkers to advance the validation of alternatives to animal testing in preclinical safety assessment. It examines especially how such principles can enhance the predictive power, mechanistic understanding, and human relevance of new approach methodologies (NAMs). Key concepts from translational medicine, such as fit-for-purpose validation, evidence-based approaches, and integrated testing strategies, are already being applied to the development and validation of NAMs. The article discusses challenges in implementing biomarker-based approaches, including standardization, demonstration of relevance, regulatory acceptance, and addressing biological complexity. It also highlights opportunities for advancement through collaborative efforts, technological innovations, and regulatory evolution. Case studies demonstrate successful applications of biomarkers in preclinical safety, while future perspectives explore emerging trends like multi-omics integration, microphysiological systems, and artificial intelligence. The article emphasizes the potential of biomarkers and translational science approaches in creating more predictive, efficient, and ethical preclinical safety assessment paradigms in the use of NAMs. Use of biomarkers can enable the mechanistic validation of human-relevant models and provide a means to relate changes in NAMs to animal or clinical study results. By leveraging these tools, the field can work towards reducing reliance on animal testing while improving the accuracy and human relevance of safety predictions.
Plain language summary: This article examines how biomarkers and translational science principles can improve safety testing without using animals. Biomarkers are quantifiable indicators of biological processes. Some of these can predict disease progression or drug effects. Translational science aims to apply laboratory findings towards clinical benefits. The article explores how combining these approaches can create better, more human-relevant and validated alternatives to animal testing. It discusses challenges that the field faces, including standardization of methods and getting regulatory acceptance. It also highlights opportunities, like integration with emerging technologies and increased global collaboration. The ultimate goal is to improve human health by streamlining NAM validation processes, i.e., show that new safety tests are more accurate, efficient, and ethical than current animal-based methods.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
HARTUNG, Thomas, Nicholas M. P. KING, Nicole KLEINSTREUER, Marcel LEIST, Danilo A. TAGLE, 2024. Leveraging biomarkers and translational medicine for preclinical safety : Lessons for advancing the validation of alternatives to animal testing. In: Alternatives to Animal Experimentation : ALTEX. Springer. 2024, 41(4), S. 545-566. ISSN 1868-596X. eISSN 1868-8551. Verfügbar unter: doi: 10.14573/altex.2410011BibTex
@article{Hartung2024Lever-71168, year={2024}, doi={10.14573/altex.2410011}, title={Leveraging biomarkers and translational medicine for preclinical safety : Lessons for advancing the validation of alternatives to animal testing}, number={4}, volume={41}, issn={1868-596X}, journal={Alternatives to Animal Experimentation : ALTEX}, pages={545--566}, author={Hartung, Thomas and King, Nicholas M. P. and Kleinstreuer, Nicole and Leist, Marcel and Tagle, Danilo A.} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/71168"> <dc:creator>Tagle, Danilo A.</dc:creator> <dcterms:title>Leveraging biomarkers and translational medicine for preclinical safety : Lessons for advancing the validation of alternatives to animal testing</dcterms:title> <dc:contributor>Hartung, Thomas</dc:contributor> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:creator>Kleinstreuer, Nicole</dc:creator> <dc:creator>Leist, Marcel</dc:creator> <dc:contributor>Kleinstreuer, Nicole</dc:contributor> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/71168"/> <dc:contributor>Tagle, Danilo A.</dc:contributor> <dc:contributor>Leist, Marcel</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-11-08T11:01:48Z</dc:date> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>King, Nicholas M. P.</dc:creator> <dcterms:issued>2024</dcterms:issued> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:language>eng</dc:language> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/71168/4/Hartung_2-1rkxceu9bezby7.pdf"/> <dc:contributor>King, Nicholas M. P.</dc:contributor> <dc:creator>Hartung, Thomas</dc:creator> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/71168/4/Hartung_2-1rkxceu9bezby7.pdf"/> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-11-08T11:01:48Z</dcterms:available> <dc:rights>terms-of-use</dc:rights> <dcterms:abstract>This article explores the potential of principles established in translational medicine for the use of biomarkers to advance the validation of alternatives to animal testing in preclinical safety assessment. It examines especially how such principles can enhance the predictive power, mechanistic understanding, and human relevance of new approach methodologies (NAMs). Key concepts from translational medicine, such as fit-for-purpose validation, evidence-based approaches, and integrated testing strategies, are already being applied to the development and validation of NAMs. The article discusses challenges in implementing biomarker-based approaches, including standardization, demonstration of relevance, regulatory acceptance, and addressing biological complexity. It also highlights opportunities for advancement through collaborative efforts, technological innovations, and regulatory evolution. Case studies demonstrate successful applications of biomarkers in preclinical safety, while future perspectives explore emerging trends like multi-omics integration, microphysiological systems, and artificial intelligence. The article emphasizes the potential of biomarkers and translational science approaches in creating more predictive, efficient, and ethical preclinical safety assessment paradigms in the use of NAMs. Use of biomarkers can enable the mechanistic validation of human-relevant models and provide a means to relate changes in NAMs to animal or clinical study results. By leveraging these tools, the field can work towards reducing reliance on animal testing while improving the accuracy and human relevance of safety predictions. Plain language summary: This article examines how biomarkers and translational science principles can improve safety testing without using animals. Biomarkers are quantifiable indicators of biological processes. Some of these can predict disease progression or drug effects. Translational science aims to apply laboratory findings towards clinical benefits. The article explores how combining these approaches can create better, more human-relevant and validated alternatives to animal testing. It discusses challenges that the field faces, including standardization of methods and getting regulatory acceptance. It also highlights opportunities, like integration with emerging technologies and increased global collaboration. The ultimate goal is to improve human health by streamlining NAM validation processes, i.e., show that new safety tests are more accurate, efficient, and ethical than current animal-based methods.</dcterms:abstract> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> </rdf:Description> </rdf:RDF>